The American Journal of Managed Care

Study: Patients With SCD Report Discrimination Based on Race, Pain, and Other Factors

A new report based on patient focus groups suggests many clinicians can do more to help patients with sickle cell disease (SCD) feel heard and understood. People with sickle cell disease (SCD) say a ...
The American Journal of Managed Care

FDA Approves Exagamglogene Autotemcel, First CRISPR Gene-Editing Therapy for SCD

The FDA has approved the first clustered regularly interspaced short palindromic repeats (CRISPR) gene-editing therapy for use in patients with sickle cell disease (SCD). Exagamglogene autotemcel (exa ...
Seeking Alpha

SCD Yields 9.27% After A 6% Distribution Bump

SCD seeks total returns with a primary focus on income, investing globally in companies with strong fundamentals and clear market advantages. The fund uses leverage to enhance returns, with interest ...
FierceBiotech

Fulcrum's sickle cell disease program is back in business after FDA lifts 6-month hold

After a six-month wait, Fulcrum Therapeutics’ sickle cell disease (SCD) plans are back on track after the FDA lifted a hold on the biotech’s candidate. The regulator instigated the full clinical hold ...
Business Wire

SCD-PROTECT publication: High SCD risk despite modern GDMT across 19,500+ LifeVest ® patients

81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...
FiercePharma

Bluebird stock plummets 18% with slow uptake of sickle cell disease gene therapy Lyfgenia

Bluebird Bio is making progress on the launch of its three approved gene therapies but appears to be trailing Vertex in its competition to attract patients to their respective treatments for sickle ...